Although ALC reductions are a concern with ozanimod treatment, the severity of lymphopenia caused by ozanimod differs from NUDT15 gene variant thiopurine-induced leukopenia; ozanimod and thiopurine affect immune cells through different mechanisms, leading to varying degrees of immune modulation.2 This evidence concerns the gene NUDT15 and lymphopenia.